Shares outstanding decreased 88.9%
Shares outstanding changed -88.9% from the comparable as-filed period. The change ranks at the 100th percentile of 8 prior comparable changes. This reverses 7 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Shares outstanding changed -88.9% from the comparable as-filed period. The change ranks at the 100th percentile of 8 prior comparable changes. This reverses 7 consecutive comparable moves in the opposite direction.
Total assets changed -35.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed -32.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed -51.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating income changed +57.5% from the comparable as-filed period.
Revenue changed -36.5% from the comparable as-filed period.
Trade receivables changed -27.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating margin changed +728 basis points from the comparable as-filed period.
Research & development changed -51.0% from the comparable as-filed period.
Net income changed -60.2% from the comparable as-filed period.
Cash & equivalents changed -40.0% from the comparable as-filed period.
Debt / assets changed +1920 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Working capital changed +82.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed -68.6% from the comparable as-filed period.
Free-cash-flow proxy changed -1052.3% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 2 consecutive comparable moves in the opposite direction.
Operating cash flow changed -801.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 2 consecutive comparable moves in the opposite direction.
SBC / revenue changed -654 basis points from the comparable as-filed period.
Receivables / revenue changed +2285 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Cash / debt changed -661 basis points from the comparable as-filed period.
Working capital / assets changed +1061 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Capital expenditure changed -99.4% from the comparable as-filed period.
Current ratio changed +39.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Debt / revenue changed +13078 basis points from the comparable as-filed period.
R&D / revenue changed -444 basis points from the comparable as-filed period.
Gross debt changed -13.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Reported total debt changed -13.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Free-cash-flow margin changed -2487 basis points from the comparable as-filed period.
Operating cash-flow margin changed -2542 basis points from the comparable as-filed period.
Net debt changed -6.7% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Capex / revenue changed -55 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.